Abstract | BACKGROUND: New evidence has suggested that people with asthma who are homozygous for arginine at aminoacid 16 of the beta2-adrenergic receptor (ADRB2) might not benefit from longacting beta2-agonist therapy. We, therefore, investigated whether ADRB2 polymorphisms affect response to longacting beta2-agonists in combination with inhaled corticosteroids. METHODS: FINDINGS: In study 1, Gly16Arg genotype had no effect on the percentage of participants with severe exacerbations across all treatment groups (99 [12%] of 833 Gly/Gly, 110 [11%] of 1028 Gly/Arg, and 32 [9%] of 361 Arg/Arg participants). Secondary endpoints, including forced expiratory volume in 1 s, peak expiratory flow, use of as-needed medication, and number of nights with awakenings were similar between genotype groups. No relation was recorded between ADRB2 haplotype and primary and secondary endpoints. In study 2, the frequency of asthma exacerbations (15 [9%] of 168 Gly/Gly, 13 [8%] of 169 Gly/Arg, and 6 [9%] of 67 Arg/Arg participants) and other study endpoints were closely similar for all ADRB2 genotypes. INTERPRETATION: Since we showed no pharmacogenetic effect of ADRB2 variation on therapeutic response in asthma, patients, irrespective of their genotype, can continue to receive inhaled corticosteroids plus longacting beta2-agonists.
|
Authors | Eugene R Bleecker, Dirkje S Postma, Rachael M Lawrance, Deborah A Meyers, Helen J Ambrose, Mitch Goldman |
Journal | Lancet (London, England)
(Lancet)
Vol. 370
Issue 9605
Pg. 2118-25
(Dec 22 2007)
ISSN: 1474-547X [Electronic] England |
PMID | 18156033
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Adrenergic beta-Agonists
- Ethanolamines
- Receptors, Adrenergic, beta-2
- Budesonide
- Salmeterol Xinafoate
- Albuterol
- Formoterol Fumarate
|
Topics |
- Adrenergic beta-Agonists
(adverse effects, therapeutic use)
- Adult
- Albuterol
(adverse effects, analogs & derivatives, therapeutic use)
- Asthma
(drug therapy, genetics)
- Budesonide
(adverse effects, therapeutic use)
- Ethanolamines
(adverse effects, therapeutic use)
- Female
- Formoterol Fumarate
- Genotype
- Humans
- Male
- Peak Expiratory Flow Rate
(drug effects)
- Pharmacogenetics
- Polymorphism, Genetic
- Randomized Controlled Trials as Topic
- Receptors, Adrenergic, beta-2
(genetics)
- Salmeterol Xinafoate
|